These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35583381)

  • 1. Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
    Lewis J; Greenway SC; Khan F; Singh G; Bhatia M; Guilcher GMT
    Am J Hematol; 2022 Oct; 97(10):1359-1371. PubMed ID: 35583381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin-1, Platelet Factor 4, and Galectin-1 Are Associated with Engraftment in Patients with Sickle Cell Disease who Underwent Haploidentical Hematopoietic Stem Cell Transplantation.
    Shaikh A; Olkhanud PB; Gangaplara A; Kone A; Patel S; Gucek M; Fitzhugh CD
    Transplant Cell Ther; 2022 May; 28(5):249.e1-249.e13. PubMed ID: 35131485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease.
    Bhat DK; Olkhanud PB; Gangaplara A; Seifuddin F; Pirooznia M; Biancotto A; Fantoni G; Pittman C; Francis B; Dagur PK; Saxena A; McCoy JP; Pfeiffer RM; Fitzhugh CD
    Front Immunol; 2021; 12():757279. PubMed ID: 34917079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study.
    Nickel RS; Flegel WA; Adams SD; Hendrickson JE; Liang H; Tisdale JF; Hsieh MM
    EClinicalMedicine; 2020 Jul; 24():100432. PubMed ID: 32637902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation.
    Leonard AK; Furstenau D; Inam Z; Luckett C; Chu R; Demirci S; Essawi K; Gudmundsdottir B; Hinds M; DiNicola J; Li Q; Eaton WA; Cellmer T; Wang X; Thein SL; Macari ER; VanNest S; Hsieh MM; Bonner M; Pierciey FJ; Tisdale JF
    Blood Adv; 2024 Apr; 8(7):1806-1816. PubMed ID: 38181784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed donor chimerism following stem cell transplantation for sickle cell disease.
    Shah NC; Rangarajan HG; Ngwube A; Shenoy S
    Curr Opin Hematol; 2023 Nov; 30(6):187-193. PubMed ID: 37694765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
    Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
    Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease-A single center experience.
    Kogel F; Hakimeh D; Sodani P; Lang P; Kühl JS; Hundsdoerfer P; Künkele A; Eggert A; Oevermann L; Schulte JH
    Pediatr Transplant; 2021 Mar; 25(2):e13892. PubMed ID: 33098344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.
    Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M
    Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
    Maris M; Storb R
    Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
    Armistead PM; Mohseni M; Gerwin R; Walsh EC; Iravani M; Chahardouli B; Rostami S; Zhang W; Neuberg D; Rioux J; Ghavamzadeh A; Ritz J; Antin JH; Wu CJ
    Exp Hematol; 2008 Sep; 36(9):1205-15. PubMed ID: 18550258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.
    Abraham A; Hsieh M; Eapen M; Fitzhugh C; Carreras J; Keesler D; Guilcher G; Kamani N; Walters MC; Boelens JJ; Tisdale J; Shenoy S; ;
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2178-2183. PubMed ID: 28882446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends.
    Shenoy S
    Hematology Am Soc Hematol Educ Program; 2011; 2011():273-9. PubMed ID: 22160045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients.
    de Azevedo JTC; Costa TCM; Lima KC; Maciel TT; Palma PVB; Darrigo-Júnior LG; Setanni Grecco CE; Stracieri ABPL; Elias JB; Pieroni F; Guerino-Cunha RL; Pinto ACS; De Santis GC; Covas DT; Hermine O; Simões BP; Oliveira MC; Malmegrim KCR
    Front Immunol; 2021; 12():774442. PubMed ID: 34956203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First successful allogeneic hematopoietic stem cell transplantation for a sickle cell disease patient in a low resource country (Nigeria): a case report.
    Bazuaye N; Nwogoh B; Ikponmwen D; Irowa O; Okugbo S; Isa I; Ighodaro E; Aina YI; Osaguona A; Idemudia O; Iyoha O; Ighosewe O; Osaghae D; Bucher C
    Ann Transplant; 2014 May; 19():210-3. PubMed ID: 24792997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
    Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
    Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.